Key clinical point: Adding rituximab to chemotherapy appears to improve EFS in B-ALL, but more than four doses are needed.
Major finding: EFS rates were 41.9% and 48.7% with SOC and SOC+rituximab, a significant difference.
Study details: The randomized, phase 3 UKALL14 trial of 577 patients.
Disclosures: Dr. Fielding is a consultant for Amgen, Novartis, Pfizer, and Incyte.
Marks D et al. ASH 2019, Abstract 739.